RAD1901

DRUG3 trials

Sponsors

Radius Pharmaceuticals, Inc., Stemline Therapeutics, Inc.

Conditions

Hot FlashesMetastatic Breast CancerVasomotor Symptoms

Phase 1

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

CompletedNCT02650817

Stemline Therapeutics, Inc.Metastatic Breast Cancer

Start: 2016-04-01End: 2019-10-18Updated: 2022-08-18

Phase 2

A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women

CompletedNCT00875420

Radius Pharmaceuticals, Inc.Hot Flashes

Start: 2009-03-31End: 2010-04-30Updated: 2018-09-26

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

TerminatedNCT02653417

Radius Pharmaceuticals, Inc.Hot Flashes, Vasomotor Symptoms

Start: 2015-12-31End: 2018-05-01Updated: 2019-03-13

Related Papers

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using <sup>18</sup>F-FES PET/CT imaging.

2020-09-1136 citations

Abstract P5-01-05: Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2- advanced/metastatic breast cancer

Cancer Research2020-02-151 citations

Abstract P1-10-04: Elacestrant, a novel oral selective estrogen receptor degrader (SERD), decreases tumoral 18F-FES uptake in a phase 1 study of ER+, HER2 -, advanced breast cancer patients

Cancer Research2018-02-151 citations

Abstract P2-08-08: A phase 1 study of RAD1901, an oral selective estrogen receptor degrader, to determine changes in the 18F-FES uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patients

Cancer Research2017-02-153 citations

Abstract P3-04-22: RAD1901 demonstrates anti-tumor activity in multiple models of ER-positive breast cancer treatment resistance

Cancer Research2017-02-152 citations

A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.

Journal of Clinical Oncology2016-05-203 citations